PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS). Source: BioSpace
Pay-for-delay deals between branded and generic drugmakers in the European Union continued to decline in 2016, according to the latest update from the European Commission. Source: Drug Industry Daily
The President’s Cancer Panel highlighted the sharp increase in U.S. cancer drug prices in a 70-page report to President Trump, calling for more value-based pricing, more competition in the drug…
Potential or actual impurities in drugs should be studied for their mutagenic properties, according to a revision to an ICH guideline addendum on mutagenic carcinogens, now adopted by the FDA.…
The FDA announced plans for additional research into the impact of drug promotion on consumers’ understanding of prescription drug risks and benefits, and said a more targeted presentation of risks…
AbbVie and Neurocrine Biosciences announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint. Source: BioSpace
Protalix BioTherapeutics believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered via injection or infusion.…
The U.S. Food and Drug Administration granted Proteostasis Therapeutics' investigational cystic fibrosis add-on therapy the Breakthrough Therapy Designation. Source: BioSpace
Tech companies have been making significant forays into the life sciences and a new report suggests that life science companies are in danger of falling behind their tech brethren.. Source:…
The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer. Source: BioSpace